Parallax Volatility Advisers’s Pacira BioSciences PCRX Stock Holding History

Parallax Volatility Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-22,500	Closed	-$424K	–	2004
2024 Q4	$424K	Sell	22,500 -5,000	-18%	-$87.8K	﹤0.01%	1537
2024 Q3	$414K	Buy	+27,500	New	+$470K	﹤0.01%	1556
2019 Q1	–	Sell	-25,000	Closed	-$1.08M	–	3667
2018 Q4	$1.08M	Hold	25,000	–	–	﹤0.01%	1281
2018 Q3	$1.23M	Buy	+25,000	New	+$1.08M	﹤0.01%	1193

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Parallax Volatility Advisers's PCRX Position: Q1 2025 in Review

Parallax Volatility Advisers sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 5,357 shares — an estimated $101K sold.

Parallax Volatility Advisers first reported a position in PCRX in Q4 2017 and held it in 8 quarters. The position peaked at $406K in Q4 2018. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

Parallax Volatility Advisers reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
Parallax Volatility Advisers sold 5,357 Pacira BioSciences shares in Q1 2025, an estimated $101K.
Parallax Volatility Advisers first reported a position in Pacira BioSciences in Q4 2017 and held it in 8 quarters.
Parallax Volatility Advisers's Pacira BioSciences position peaked at $406K in Q4 2018.
235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Parallax Volatility Advisers's 13F filing for Q1 2025, filed 15 May 2025.